文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

过继细胞疗法治疗实体瘤:当前的挑战与新兴治疗进展。

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.

机构信息

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China; School of Medicine, Shanghai University, Shanghai 200444, China; Shanghai Engineering Research Center for Topical Chinese Medicine, Shanghai 200443, China.

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Shanghai Engineering Research Center for Topical Chinese Medicine, Shanghai 200443, China; Department of Pharmacy, First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.

出版信息

J Control Release. 2024 Apr;368:372-396. doi: 10.1016/j.jconrel.2024.02.033. Epub 2024 Mar 6.


DOI:10.1016/j.jconrel.2024.02.033
PMID:38408567
Abstract

Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to the complex tumor microenvironment that affects the localization and killing ability of the CAR cells. Solid tumors with a strong immunosuppressive microenvironment and complex vascular system are unaffected by CAR cell infiltration and attack. To improve their efficacy toward solid tumors, CAR cells have been modified and upgraded by "decorating" and "pruning". This review focuses on the structure and function of CARs, the immune cells that can be engineered by CARs and the transformation strategies to overcome solid tumors, with a view to broadening ideas for the better application of CAR cell therapy for the treatment of solid tumors.

摘要

嵌合抗原受体(CAR)表达免疫细胞的过继细胞免疫疗法是一种高度特异的抗肿瘤免疫疗法,在治疗血液系统恶性肿瘤方面显示出良好的效果。然而,由于影响 CAR 细胞定位和杀伤能力的复杂肿瘤微环境,其在实体瘤治疗方面的进展较为缓慢。具有强烈免疫抑制微环境和复杂血管系统的实体瘤不受 CAR 细胞浸润和攻击的影响。为了提高 CAR 细胞对实体瘤的疗效,CAR 细胞已通过“修饰”和“修剪”进行了改造和升级。本综述重点介绍了 CAR 的结构和功能、可通过 CAR 工程化的免疫细胞以及克服实体瘤的转化策略,以期为更好地应用 CAR 细胞疗法治疗实体瘤拓宽思路。

相似文献

[1]
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.

J Control Release. 2024-4

[2]
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.

Mol Cancer. 2023-1-30

[3]
Recent Advances in CAR-Based Solid Tumor Immunotherapy.

Cells. 2023-6-11

[4]
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.

Stem Cell Res Ther. 2022-9-24

[5]
Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.

Pharmacol Res. 2022-10

[6]
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.

Mol Cancer. 2018-1-12

[7]
Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.

Front Immunol. 2022

[8]
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.

Front Immunol. 2019-2-5

[9]
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Front Immunol. 2022

[10]
Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.

Cancer J.

引用本文的文献

[1]
Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 T cell exhaustion-suppressed antitumor immunity.

Sci Adv. 2025-8-15

[2]
T cells in cancer: mechanistic insights and therapeutic advances.

Biomark Res. 2025-7-15

[3]
Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.

Front Pharmacol. 2025-6-12

[4]
The progress and prospects of targeting the adenosine pathway in cancer immunotherapy.

Biomark Res. 2025-5-19

[5]
Liver Metastasis in Cancer: Molecular Mechanisms and Management.

MedComm (2020). 2025-2-27

[6]
SPRY1 regulates macrophage M1 polarization in skin aging and melanoma prognosis.

Transl Oncol. 2025-4

[7]
CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors.

Cancer Immunol Immunother. 2025-1-3

[8]
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy.

J Hematol Oncol. 2024-11-13

[9]
Natural killer cell-based cancer immunotherapy: from basics to clinical trials.

Exp Hematol Oncol. 2024-10-16

[10]
Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions.

Transl Oncol. 2024-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索